- Home
- IFRX
IFRX
InflaRx N.V.
as 06-13-2025 4:00pm EST
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
| Founded: | 2007 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 65.8M | IPO Year: | 2017 |
| Target Price: | $7.75 | AVG Volume (30 days): | 850.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.71 - $2.81 | Next Earning Date: | 08-07-2025 |
| Revenue: | $140,242 | Revenue Growth: | 30.90% |
| Revenue Growth (this year): | 3.36% | Revenue Growth (next year): | 100.60% |
Latest InflaRx N.V. News
IFRX Breaking Stock News: Dive into IFRX Ticker-Specific Updates for Smart Investing
Pharma Voice
13 days ago
COVID’s remaining biotech contenders navigate a dwindling market
MT Newswires
17 days ago
Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating
MT Newswires
17 days ago
Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13
MT Newswires
18 days ago
Top Midday Decliners
MT Newswires
18 days ago
InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell
GlobeNewswire
18 days ago
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
GlobeNewswire
24 days ago
InflaRx to Participate in Upcoming Investor Conferences
Simply Wall St.
a month ago
InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)
Compare IFRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IFRX InflaRx N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.